B7-H3-Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors.

导出 OA

翻译打印收藏纠错

作者： Licui,Jiang ^[1] ; Fengtao,You ^[2] ; Hai,Wu ^[1] ; Changsong,Qi ^[3] ; Shufen,Xiang ^[2] ; Ping,Zhang ^[4] ; Huimin,Meng ^[2] ; Min,Wang ^[4] ; Jiequn,Huang ^[2] ; Yafen,Li ^[2] ; Dan,Chen ^[2] ; Gangli,An ^[1] ; Nan,Yang ^[2] ; Bozhen,Zhang ^[5] ; Lin,Shen ^[3] ; Lin,Yang ^[6]

作者单位： Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China. ^[1] PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China. ^[2] State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital and Institute, Beijing, China. ^[3] PersonGen.Anke Cellular Therapeutics Co., Ltd., Hefei, China. ^[4] PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China.;PersonGen.Anke Cellular Therapeutics Co., Ltd., Hefei, China. ^[5] Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China.;PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China.;PersonGen.Anke Cellular Therapeutics Co., Ltd., Hefei, China. ^[6]